X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Compared to vehicle, reproxalap demonstrated statistically significant and clinically relevant improvements in subject-reported ocular itching and tearing and investigator-assessed ocular redness over the duration of exposure in the allergen chamber.
Lead Product(s): Reproxalap
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: La Jolla Pharmaceutical
Deal Size: $59.0 million Upfront Cash: $43.0 million
Deal Type: Acquisition June 24, 2020
Details:
Through this acquisition, Melinta will enhance its commercial portfolio with XERAVATM. Once the transaction closes, Melinta will have a portfolio of five complementary marketed antibiotics: VABOMERE, ORBACTIV, BAXDELA, MINOCIN for Injection, and XERAVATM.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: $55.0 million Upfront Cash: $55.0 million
Deal Type: Merger June 09, 2020
Details:
Tetraphase and AcelRx entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain.
Lead Product(s): Eravacycline
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals
Deal Size: $26.9 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 16, 2020
Details:
The company intends to use the net proceeds from the registered direct offering and concurrent private placement for the commercialization of XERAVA as well as for working capital and other general corporate purposes.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Capital
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Financing January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
